Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
CELU
Celularity Inc.
The company monetizes its manufacturing capabilities by offering contract development/manufacturing services to third parties.
|
$41.19M |
$1.73
-11.54%
|
|
ICCM
IceCure Medical Ltd
IceCure manufactures liquid nitrogen-based cryoablation medical devices (ProSense/XSEN) used for tumor destruction, i.e., medical devices & biometrics.
|
$39.86M |
$0.73
+1.92%
|
|
ANVS
Annovis Bio, Inc.
The lead candidate Buntanetap is positioned as an Alzheimer's disease (AD) therapeutics program with cognition endpoints and an FDA-aligned path toward NDA filings.
|
$39.36M |
$2.02
-3.81%
|
|
BCAB
BioAtla, Inc.
Oz-V and Mec-V are ADCs (CAB-ROR2-ADC, CAB-AXL-ADC) - major product modality.
|
$38.81M |
$0.66
-5.33%
|
|
RNTX
Rein Therapeutics Inc.
IPF/related fibrotic orphan indications classify Rein's lead assets as addressing a rare disease space.
|
$38.77M |
$1.75
+12.14%
|
|
ELUT
Elutia Inc.
Elutia's EluPro is a cardiology device used with cardiac implanted electronic devices (CIEDs), directly tying to Cardiology Devices.
|
$38.45M |
$0.95
+4.22%
|
|
VERU
Veru Inc.
Veru's lead asset enobosarm is an oral small molecule therapeutic.
|
$38.11M |
$2.60
-11.86%
|
|
NMTC
NeuroOne Medical Technologies Corporation
Core product category: neuromodulation devices used to treat epilepsy and pain via brain stimulation and ablation.
|
$38.07M |
$0.75
-4.73%
|
|
JANL
Janel Corporation
Life Sciences activities include recombinant proteins and enzymes production (antibodies, reagents).
|
$37.96M |
$32.00
|
|
ECOR
electroCore, Inc.
Directly markets and sells neuromodulation medical devices (gammaCore, Quell, Truvaga, Sparrow Ascent, TAC-STIM).
|
$37.70M |
$5.08
+0.79%
|
|
YI
111, Inc.
Private label medical devices and biometrics offerings under the healthcare product lineup.
|
$37.46M |
$4.43
+1.49%
|
|
RMTI
Rockwell Medical, Inc.
Rockwell Medical's core offerings are dialysis-related consumables (acid and bicarbonate concentrates, single-use bicarbonate cartridge, and at-home packs) used with dialysis equipment.
|
$36.91M |
$1.06
-4.05%
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$36.90M |
$9.92
-2.55%
|
|
KTCC
Key Tronic Corporation
Vietnam medical device manufacturing capability highlighted, aligning with Medical Devices & Biometrics.
|
$36.27M |
$3.46
-2.81%
|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$36.18M |
$4.47
-0.89%
|
|
MURA
Mural Oncology plc
Company develops oncology-focused immunotherapies, including engineered cytokine therapies (nemvaleukin) and related assets.
|
$36.09M |
$2.08
-0.24%
|
|
RDGL
Vivos Inc.
RDGL's core offering is radiopharmaceutical therapy using Y-90 for targeted cancer treatment.
|
$36.05M |
$0.08
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$35.90M |
$0.73
-2.80%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$35.33M |
$5.25
-4.72%
|
|
DSY
Big Tree Cloud Holdings Limited
Provides OEM/ODM manufacturing services, i.e., contract manufacturing for others.
|
$35.11M |
$0.64
+4.77%
|
|
ZYXI
Zynex, Inc.
Directly manufactures medical devices and biometrics used for patient monitoring and non-opioid pain management.
|
$35.08M |
$1.16
+0.87%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$34.98M |
$2.34
-4.10%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$34.70M |
$1.14
-7.32%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$34.34M |
$1.31
-5.76%
|
|
IKNA
Ikena Oncology, Inc.
ImageneBio's lead asset IMG-007 is a monoclonal antibody targeting OX40 for immunological/inflammatory diseases, aligning with Immunology Therapeutics.
|
$33.78M |
$8.71
|
|
IGC
IGC Pharma, Inc.
Direct Alzheimer’s disease therapeutics pipeline with IGC-AD1 and disease-modifying candidates, the core product focus.
|
$33.74M |
$0.40
+1.19%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$32.93M |
$3.54
-2.08%
|
|
MLSS
Milestone Scientific Inc.
Direct dental equipment manufacturing (DPS-based systems and related dental devices) as the dental segment is a core business.
|
$32.88M |
$0.42
-0.98%
|
|
LESL
Leslie's, Inc.
AccuBlue water-testing systems and related diagnostic testing capabilities are direct testing instruments offered to customers.
|
$32.63M |
$3.54
+0.43%
|
|
DYAI
Dyadic International, Inc.
Company directly produces recombinant proteins and enzymes (e.g., RHSA, transferrin, DNase1, RNase inhibitors, FGF, lactalbumin, lactoferrin) for life sciences, diagnostics, and food/industrial uses.
|
$32.50M |
$1.08
-4.42%
|
|
RADX
Radiopharm Theranostics Limited
Core product category: Radiopharmaceuticals used for diagnostic imaging and therapy in oncology.
|
$32.22M |
$5.30
+0.76%
|
Showing page 30 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
